On Thursday, PTC Therapeutics received an upgrade to its Relative Strength (RS) Rating, from 70 to 73.
Can You Really Time The Stock Market?
This exclusive rating from Investor's Business Daily tracks market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the trailing 52 weeks compares to all the other stocks in our database.
Decades of market research reveals that the best-performing stocks often have an 80 or better RS Rating as they launch their largest price moves. See if PTC Therapeutics can continue to rebound and clear that threshold.
While the stock is not near a proper entry right now, see if it is able to form and break out from a proper base.
PTC Therapeutics posted 0% earnings growth in its most recent report, while sales growth came in at -4%.
PTC Therapeutics holds the No. 145 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Rigel Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
